NetworkNewsBreaks

FridayFeb 24, 2017 11:10 am

NetworkNewsBreaks – Auris Medical’s (NASDAQ: EARS) AM-111 Receives FDA Fast Track Designation to Treat Acute Sensorineural Hearing Loss

Auris Medical (NASDAQ: EARS) shares rose 13% this morning on news of the reception of Fast Track designation for AM-111 in the treatment of acute sensorineural hearing loss (ASNHL) from the U.S. Food and Drug Administration (FDA). The company is currently evaluating AM-111 in two phase 3 clinical trials. The first is the HEALOS trial, which is being conducted in several European and Asian countries. Auris Medical expects to complete enrollment in the second quarter of 2017 and report top-line results from this trial in the third quarter of 2017. The second trial, ASSENT, is being conducted in the U.S.,…

Continue Reading

ThursdayFeb 23, 2017 11:30 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 23, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PTX 50.36% – News: Receives favorable opinion in Zohydro® ER ANDA litigation NVFY 29.28% – News: Reports over 1,000 individuals paid and completed training on Nova-Mart in February HMNY 16.99% – News: Launches free hate crime mapping on RedZone Map ETST 16.00% – News: Begins composition of 2 new pharmaceutical drugs, 3 nutraceutical patent studies AVEO 12.67% – News: Passes the first safety review for TIVO-3 by SMC EQUR 9.23% – News: Receives FDA…

Continue Reading

ThursdayFeb 23, 2017 11:28 am

NetworkNewsBreaks – MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) Receives Regulatory Green Light for Clinical Trial of Pancreatic Cancer Candidate

MabVax Therapeutics (NASDAQ: MBVX) is trading higher after announcing it has received authorization from the FDA for the initiation of a phase I clinical trial with MVT-1075 as a therapeutic treatment for pancreatic cancer. MVT-1075 is the company's novel, fully human antibody radioimmunotherapy. In this initial phase I trial the company plans to evaluate the safety, dosimetry, and pharmacokinetics of MVT-1075 with patient disease status evaluated based on tumor measurements using RECIST 1.1 criteria. The company intends to initiate the phase I clinical trial in the first half of 2017. "We are executing on the development strategy we have outlined…

Continue Reading

ThursdayFeb 23, 2017 11:26 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Adds Over 100 New Agents and Brokers in Tough Climate

While market reports show low inventory of houses on the market, eXp World Holdings doesn’t seem to be affected by the overall concern for real estate businesses in the United States. In fact, the company continues to grow. “Although the end of 2016 showed cause for concern for real estate businesses across the country, inventory for January moved at a 4% faster annual rate (http://nnw.fm/obP83). This stronger than usual off-season has left a low volume of available homes for sale with very high prices. But this dip in volume has not halted the rising interest in eXp World Holdings, Inc.…

Continue Reading

ThursdayFeb 23, 2017 11:21 am

NetworkNewsBreaks – Singlepoint, Inc. (SING) Forecasts Growth through Acquisitions, Joint Ventures in 2017

Singlepoint’s (OTC: SING) founder, president and CEO Greg Lambrecht recently gave an interview on Money TV with Donald Baillargeon, discussing the company’s acquisition strategy and recent stock performance. “The company’s massive success on the market in terms of stock price and volume has also drawn the interest of institutional investors. We’re getting a lot of attention from Wall Street and other that, even though we’re a Pink and right now we’re offering rule 144, that doesn’t seem to bother them. With our volume and stock price, we have a lot of interested parties that want to invest in Singlepoint and I…

Continue Reading

ThursdayFeb 23, 2017 11:19 am

NetworkNewsBreaks – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Shares Tumble on Disappointing Phase 3 Clinical Trial of Leukemia Candidate

Shares of Cyclacel Pharmaceuticals (NASDAQ: CYCC) are down more than 15% after the company reported that its lead candidate failed to meet its primary endpoint in a phase 3 study of elderly patients with acute myeloid leukemia (AML). The trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival (OS) for the experimental arm versus an active control. The secondary endpoint, an improved rate of complete remission (CR), was observed in patients who had discontinued therapy at the time of analysis. Full results from the SEAMLESS study will be submitted for presentation at an upcoming…

Continue Reading

WednesdayFeb 22, 2017 1:27 pm

NetworkNewsBreaks – Internap Corp. (NASDAQ: INAP) Shares Surge on $43M Private Placement, Revenue Guidance

Internap (NASDAQ: INAP) traded 26% higher mid-day after the company announced the private placement of approximately 23.8 million shares of its common stock at a price of $1.81 per share, for total gross proceeds of approximately $43 million. The funding in the private placement is provided by a group of investors that include affiliates of or funds managed by GAMCO Investors, Inc. and accounts advised by Avenir Corporation. The company intends to use the net proceeds of the offering to reduce debt. The settlement date for the transaction is February 27, 2017. Additionally, INAP reaffirmed guidance for 2016, including revenue…

Continue Reading

WednesdayFeb 22, 2017 1:23 pm

NetworkNewsBreaks – Zogenix, Inc. (NASDAQ: ZGNX) Has ‘Buy’ Rating Reiterated by Aegis Capital; Reaches Key Milestone in ZX008 Dravet Syndrome Phase 3 Program

Zogenix (NASDAQ: ZGNX) has been reiterated at a 'Buy' rating and $28 price target by Aegis Capital Corp. The company recently announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome, a key milestone in the company’s phase 3 program. The two-cohort study will assess the pharmacokinetic and safety profile of single doses of ZX008, clobazam and valproate when added to stiripentol, followed by an evaluation of the efficacy, safety and tolerability of ZX008 as adjunctive antiepileptic therapy to a drug regimen that includes stiripentol, clobazam and valproate in a randomized, double-blind,…

Continue Reading

WednesdayFeb 22, 2017 1:20 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Has ‘Buy’ Rating Reiterated by Aegis Capital

Noting Vanda Pharmaceuticals’ (NASDAQ: VNDA) recent financials and 2017 guidance, Aegis Capital Corp. has reiterated its 'Buy' rating and $24 price target on the company’s stock. Vanda reported net product sales for its melatonin receptor agonist, HETLIOZ®, at $71.7 million for full-year 2016, an increase of 62% compared to $44.3 million for the full year 2015. Fanapt®, the company’s atypical antipsychotic, brought in $74.3 million for the full year 2016, a 13% increase compared to $65.6 million in 2015. For the fourth quarter of 2016, Vanda reported non-GAAP net income of $3.6 million, compared to a non-GAAP net loss of…

Continue Reading

WednesdayFeb 22, 2017 11:17 am

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 22, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: TECR 43.59% – News: Chairman, CEO releases letter to shareholders SNGX 29.55% – News: Receives European patent for proprietary formulation of synthetic hypericin LNTH 22.99% – News: Moving on momentum from recent deal with GE Healthcare BIVI 20.00% – News: Submits response to FDA for BIV201 IND CDIF 15.68% – News:  Uplists to OTCQB venture market ZENO 15.00% – News: Initiates MIDS Medical Limited priority testing ESDI 13.55% – News: Endorses Craft Beverage Modernization…

Continue Reading